# A Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With Apatinib

> **NCT06280105** · PHASE2 · RECRUITING · sponsor: **Meng Chao Hepatobiliary Hospital of Fujian Medical University** · enrollment: 40 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Cadonilimab+regorafenib

## Key facts

- **NCT ID:** NCT06280105
- **Lead sponsor:** Meng Chao Hepatobiliary Hospital of Fujian Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-31
- **Primary completion:** 2026-03-31
- **Final completion:** 2027-03-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06280105

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06280105, "A Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With Apatinib". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06280105. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*